Phosphodiesterase 5 inhibition to treat essential hypertension: Is this the beginning of the story?

Hypertension

Volumn 48, Issue 4, 2006, Pages 546-548

  Taddei, Stefano ^a   Ghiadoni, Lorenzo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

ARTERY BLOOD FLOW; BLOOD PRESSURE REGULATION; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PULMONARY HYPERTENSION; PULSE WAVE; HYPERTENSION; NOTE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; HUMANS; HYPERTENSION; PHOSPHODIESTERASE INHIBITORS;

EID: 33750594768     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000241985.54400.85     Document Type: Editorial

References (11)

1. Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
2. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension. 2006;48:622-627.
3. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoform. Physiol Rev. 1995;75:725-748.
4. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation. 2003;108:239-244.
5. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002;40:505-510.
6. Van Bortel LM, Struijker-Boudier HA, Safar ME. Pulse pressure, arterial stiffness, and drug treatment of hypertension. Hypertension. 2001;38:914-921.
7. Safar ME, London GM. Therapeutic studies and arterial stiffness in hypertension: Recommendations of the European Society of Hypertension. The Clinical Committee of Arterial Structure and Function. Working Group on Vascular Structure and Function of the European Society of Hypertension. J Hypertens. 2000;18:1527-1535.
8. Nichols WW, O'Rourke MF. McDonaldd's Blood Flow in Arteries: Theoretic, Experimental and Clinical Principles. 5th ed. London, United Kiingdom: Edwin Arnold; 2005.
9. Stokes GS, Barin ES, Gilfillan KL. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. Hypertension. 2003;41:298-301.
10. Taddei S, Ghiadoni L, Virdis A, Buralli S, Salvetti A. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired NO availability in essential hypertensive patients. Circulation. 1999;100:1400-1405.
11. Deanfield J, Donald A, Ferri C, Halcox J, Halligan S, Lerman A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds. A statement by the Working Group on Endothelin and Endothelial Factors of the ESH. J Hypertens. 2005;23:7-17.